PatternsRadar
Sign in

SYNCOMFSyncom Formulations (India) Limited

NSE
Full chart
23.22INR+0.08 (+0.35%)Close · 6 Oct 2026
11 Aug 2026Last results
HealthcareSector
Pharmaceuticals & BiotechnologyIndustry
₹2,183 CrMarket cap
25.5P/E (TTM)
25.2%Delivery

Filings & corporate actions

13 results filed
CSV
Next results · Q2 FY27
Expected 9 Nov 2026 – 12 Nov 2026
Estimate: filed 40–43 days after quarter end, last 3 times
Dividend
₹0.10 per share · last 23 Sept 2026
2026
  • 23 SeptdividendDividend · ₹0.10 per share-1.9%
  • 11 AugresultsResults · Q1 FY27 · consolidated and standalone+9.3%NSE
  • 20 JulshareholdingShareholding · 30 Jun 2026+0.7%NSE
  • 22 MayresultsResults · Q4 FY26 · consolidated and standalone+10.5%NSE
  • 16 AprshareholdingShareholding · 31 Mar 2026+1.1%NSE
  • 12 FebresultsResults · Q3 FY26 · consolidated and standalone-2.0%NSE
  • 9 JanshareholdingShareholding · 31 Dec 2025-3.1%NSE

Reaction to results · all yearsrose on day 0 in 7 of 13 CSV

QuarterFiledDay 0+5D+20DRel vol
Q1 FY2711 Aug 2026+9.3%+5.5%+38.6%27.7×
Q4 FY2622 May 2026+10.5%+4.1%-3.2%14.4×
Q3 FY2612 Feb 2026-2.0%-8.0%-17.1%1.3×
Q2 FY2612 Nov 2025+1.9%-2.2%-8.6%2.7×
Q1 FY268 Aug 2025-1.1%-4.4%-5.9%1.1×
Q4 FY2520 May 2025+4.3%+16.6%+7.1%8.5×
Q3 FY2510 Feb 2025+1.3%-7.4%-13.2%3.9×
Q2 FY2512 Nov 2024-4.6%-8.0%+2.7%1.3×
Q1 FY2512 Aug 2024-1.3%+19.3%+54.0%1.4×
Q4 FY2417 May 2024+1.5%-5.2%-6.0%0.6×
Q3 FY2415 Feb 2024-1.0%-1.0%-19.3%0.4×
Q2 FY249 Nov 2023+13.2%+11.5%+26.9%8.7×
Q1 FY2414 Aug 2023-5.1%+1.7%-5.1%1.2×
Average+2.1%+1.7%+3.9%

Close-to-close from the session before the filing could trade. Day 0 is the first session after it.

Growth · Q1 FY27

CSV
Revenue YoY+7.4%
Profit YoY+57.7%
Interest cost YoY+58.4%
Revenue QoQ-7.3%
Profit QoQ-1.3%
CAGR2Y3Y4Y5Y6Y7Y
Revenue+30.8%—————
Profit+73.1%—————

Key data

CSV
Open23.14
Day range22.77 – 23.83
52-week range10.21 – 27.49
From 52w high-15.5%
RSI (14)62.3
ATR (14)1.69
Volume1.53Cr
Avg volume (20D)3.09Cr
Rel volume0.50×
Volatility (1Y)46.1%
Turnover₹35.6Cr
SMA 50 / 20017.92 / 14.62

Delivery percentage

Latest · 6 Oct 202625.2%
20-day avg30.3%
1-year avg50.1%
Percentile (own history)1st
Range10.1–100.0%
Sessions963

Over the last 20 sessions SYNCOMF settled 30.3% of its traded quantity, which is ordinary for an NSE equity. Its one-year average is 50.1%, so recent sessions are running 19.8 points lower than usual. The latest session ranks higher than 1% of the 963 sessions on record for it.

What delivery percentage measuresScan the whole market on delivery

IndustryPharmaceuticals
PeersDIVISLABLAURUSLABSSUNPHARMAWOCKPHARMADRREDDYMOREPENLAB

Performance returns

CSV
1D1W1M3M6M1Y
Price+0.35%+4.59%+8.71%+67.17%+105.49%+39.96%

Valuation

CSV
Market cap₹2,183 Cr
P/E (TTM)25.5
EPS (TTM)0.91
Shares outstanding94.00Cr
Listed18 Nov 2022

Ownership

CSV
Promoter50.57%
Promoter Δ QoQ0.00 pp
Public49.43%
FII0.35%
DII0.00%
Pledged0.00%

Quarterly results · consolidated

CSV
Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue (₹ Cr)121.7115.1135.4125.5
YoY chg+19.0%-9.7%-9.0%+7.4%
Net profit (₹ Cr)16.618.925.224.8
YoY chg+49.4%+45.4%+42.3%+57.7%
Net margin13.6%16.4%18.6%19.8%
EPS0.180.230.270.26

Shareholding over time

CSV

By quarter

30 Jun 2026 · promoter 50.57% · public 49.43%
11 Nov 2022: promoter 50.57%31 Dec 2022: promoter 50.57%31 Mar 2023: promoter 50.57%30 Jun 2023: promoter 50.57%30 Sept 2023: promoter 50.57%31 Dec 2023: promoter 50.57%31 Mar 2024: promoter 50.57%30 Jun 2024: promoter 50.57%30 Sept 2024: promoter 50.57%31 Dec 2024: promoter 50.57%31 Mar 2025: promoter 50.57%30 Jun 2025: promoter 50.57%30 Sept 2025: promoter 50.57%31 Dec 2025: promoter 50.57%31 Mar 2026: promoter 50.57%30 Jun 2026: promoter 50.57%
2022-112026-06
  • Promoter
  • Public and others
Promoter
50.57%
Public
49.43%
Promoter change
0.00 pp
Filed
20 Jul 2026
FII
0.35%
DII
0.00%
Promoter pledged
0.00%

Promoter and public shares of total equity, from the pattern filed each quarter. Institutional and pledge figures come from a separate filing stage whose backfill is still running, so they are absent for almost every instrument rather than zero.

Financials · quarterly statement

CSV
₹ crore, as filed
 Q2 FY24Q3 FY24Q4 FY24AQ1 FY25Q2 FY25Q3 FY25Q4 FY25AQ1 FY26Q2 FY26Q3 FY26Q4 FY26AQ1 FY27
Revenue from operations63.865.174.687.3102.3127.5148.9116.9121.7115.1135.4125.5
Other income4.04.63.11.34.14.06.96.05.35.514.67.8
Total income67.869.777.788.6106.5131.6155.8122.9127.0120.6150.0133.4
Total expenses59.460.367.678.591.6114.3132.5102.7104.995.6116.3101.1
└ Finance costs1.11.11.20.40.20.20.10.30.30.30.40.2
└ Depreciation0.91.41.31.31.31.31.31.31.41.42.51.5
Profit before tax8.49.410.010.114.917.323.320.322.025.133.732.3
Tax expense1.92.42.62.53.74.35.64.55.46.28.57.4
Net profit6.57.07.47.611.113.017.715.816.618.925.224.8
EPS0.080.090.100.110.160.140.160.210.180.230.270.26
Net margin10.20%10.75%9.93%8.75%10.86%10.19%11.89%13.48%13.64%16.42%18.59%19.79%
PBT margin13.24%14.37%13.45%11.58%14.51%13.54%15.65%17.36%18.10%21.79%24.89%25.69%
Tax rate22.93%25.21%26.18%24.45%25.20%24.68%24.06%22.36%24.67%24.63%25.30%22.96%

A audited · R restated by a later filing · negatives in parentheses. EPS and the share count are restated onto the same split-adjusted basis as the price chart, so they can be read against it; every rupee figure is exactly as filed. A quarterly filing carries a profit and loss only — there is no balance sheet behind it, and so no debt, cash flow or return-on-capital figure here. Latest filed 11 Aug 2026.

SYNCOMF at a glance

  • SYNCOMF closed at ₹23.22 on 6 Oct 2026, +0.35% on the day, +40.0% over one year, 15.5% below its 52-week high of ₹27.49.
  • Delivery was 25.2% of traded quantity on 6 Oct 2026, the 1st percentile of its own 963 sessions with a reading (20-session average 30.3%, 1-year average 50.1%).
  • Market capitalisation is ₹2,183 crore at a trailing P/E of 25.5 (trailing EPS ₹0.91).
  • Q1 FY27 results (consolidated, filed 11 Aug 2026): revenue ₹126 crore (+7.4% year on year), net profit ₹25 crore (+57.7%); the price moved +9.3% on the first session after.
  • Promoters held 50.57% at 30 Jun 2026, unchanged on the previous filing.
  • Q2 FY27 results are expected between 9 Nov 2026 and 12 Nov 2026, going by past filing dates — an estimate, not an announcement.

About

CSV
Macro sectorHealthcare
Basic industryPharmaceuticals
ISININE312C01025
SeriesEQ
Listed18 Nov 2022
History from18 Nov 2022
Sessions963
Turnover rank#386

Prices are adjusted for splits and bonuses. Delivery figures come from NSE’s daily reports and are unavailable for older sessions. Sourced from the eod2 dataset, last updated 6 Oct 2026.

More in Pharmaceuticals & Biotechnology

CSV

All Pharmaceuticals & Biotechnology stocks on the NSEAll Healthcare stocks on the NSE